NCT01994109View on ClinicalTrials.gov

Efficacy and Safety Study of MYOBLOC® Followed by Open-Label Multiple-Treatment With MYOBLOC® in the Treatment of Troublesome Sialorrhea in Adult Subjects

PHASE3CompletedINTERVENTIONAL
Enrollment

187

Participants

Timeline

Start Date

November 30, 2013

Primary Completion Date

January 31, 2016

Study Completion Date

January 31, 2017

Conditions
Sialorrhea
Interventions
DRUG

MYOBLOC

"MYOBLOC (rimabotulinumtoxinB) Injection, or botulinum toxin type B, is the B serotype of botulinum toxin. It is the only commercially available B serotype, and also the only available botulinum toxin that does not require reconstitution for use."

OTHER

PLACEBO

Trial Locations (34)

10003

New York

12208

Albany

20007

Washington D.C.

21075

Elkridge

21287

Baltimore

29935

Port Royal

33010

Rivne

33486

Boca Raton

33980

Port Charlotte

38018

Cordova

45219

Cincinnati

46032

Carmel

48334

Detroit

49027

Dnipropetrovsk

61068

Kharkiv

63110

St Louis

74136

Tulsa

76008

Ivano-Frankivsk

77030

Houston

78229

San Antonio

79010

Lviv

80045

Aurora

84132

Salt Lake City

88018

Uzhhorod

90033

Los Angeles

91950

National City

92354

Loma Linda

98034

Kirkland

98409

Tacoma

188643

Vsevolozhsk

198510

Saint Petersburg

660037

Krasnoyarsk

664079

Irkutsk

08818

Edison

All Listed Sponsors
lead

Supernus Pharmaceuticals, Inc.

INDUSTRY

NCT01994109 - Efficacy and Safety Study of MYOBLOC® Followed by Open-Label Multiple-Treatment With MYOBLOC® in the Treatment of Troublesome Sialorrhea in Adult Subjects | Biotech Hunter | Biotech Hunter